AstraZeneca PLC (AZN) financials
NYSE · Healthcare · Drug Manufacturers - General · 96,100 employees · CEO Pascal Claude Roland Soriot
- Price
- $186.65 +7.02%
- Market cap
- $289B
- Enterprise value
- $316B
- Last report
- Q3 '26 filed 2026-10-30
- Next report
- 2027-02-09 EPS est. $2.41
Revenue (TTM)$62.2B+7.0% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)23.7%+1.6 pp vs a year agoOperating income $14.7B
Net income (TTM)$11B+16.9% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)$9.32B-2.6% vs a year agoCapex $4.01B
Diluted EPS (TTM)$7.01+16.4% vs a year agoSum of the last 4 quarters
Net cash-$26B-6.1% vs a year agoCash + short-term investments - debt
Valuation & key figures
- Market cap
- $289B EV $316B
- Revenue
- $62.2B Trailing 12 months
- Revenue growth
- +7% FY2026 consensus
- Profit margin
- 17.7% Net income / revenue, TTM
- P/E
- 26.3× Forward 18.2× (FY2026)
- P/S
- 4.6× Price / sales, TTM
- EV / EBITDA
- 14.8× TTM
- Free cash flow
- $9.32B Trailing 12 months
- Net income
- $11B Trailing 12 months
- Revenue estimate
- $62.9B FY2026 consensus
- Earnings
- 2027-02-09 Revenue est. $16.7B
- Dividend
- $3.23 Per share, last 12 months
Key takeaways
Computed from the reported numbers - every statement carries the figure it rests on.
- Last report (2026-10-30): revenue beat by 1.3%, EPS beat by 7.3%Revenue $16.2B vs $16B expected (+1.3%); EPS $2.79 vs $2.60 (+7.3%).
- Revenue growth slowing: 5.3% year on yearQ3 '26 revenue $16B, against an average of 8.8% over the four quarters before.
- Operating margin 23.7% (TTM), +1.6 pp on a year agoOperating income grew 14.9% while revenue grew 7.0%.
- 11.0% of pre-tax profit is eaten by non-operating lossesPre-tax income $13.2B vs operating income $14.7B (TTM). Losses on equity stakes and other one-off items cut net income and EPS - operating income is the cleaner measure of the business.
- Capex 6.5% of revenue (a year ago 9.6%)$4.01B invested in the last 4 quarters (-28.0% on a year earlier). Free cash flow $9.32B = 84.8% of net income.
- Returned $5.27B to shareholders = 56.6% of free cash flowBuybacks $349M (a year earlier $12.8M), dividends $4.93B, stock-based pay $0 (TTM).
- Diluted share count down 0.1% in a year1.56B diluted shares in Q3 '26, 1.56B a year earlier.
- Net debt $26BCash + short-term investments $8.15B, debt incl. leases $34.1B; a year ago net debt $24.5B.
Last quarter: Q3 '26
Quarter ended 2026-09-30. Compared with the same quarter a year earlier and with the analyst consensus before the report.
Quarter vs a year ago
| Q3 '26 | Year ago | Change | |
|---|---|---|---|
| Revenue | $16B | $15.2B | +5.3% |
| Gross margin | 74.6% | 81.6% | -6.9 pp |
| Operating income | $4.32B | $3.58B | +20.6% |
| Operating margin | 27.0% | 23.6% | +3.4 pp |
| Net income | $3.08B | $2.53B | +21.4% |
| Diluted EPS | $1.97 | $1.62 | +21.6% |
| Operating cash flow | $4.66B | $5.13B | -9.3% |
| Capex | $667M | $1.73B | -61.4% |
| Free cash flow | $3.99B | $3.41B | +17.1% |
| R&D | $3.6B | $3.66B | -1.8% |
| Stock-based compensation | $0 | $0 | – |
Reported vs consensus
2026-10-30| Actual | Consensus | vs consensus | |
|---|---|---|---|
| Revenue | $16.2B | $16B | +1.3% |
| EPS (as estimated) | $2.79 | $2.60 | +7.3% |
From the report of 2026-10-30 for Q3 '26: revenue and the EPS analysts estimate (often adjusted), so it can differ from the EPS of the statements above.
EPS vs consensus
last 8 reportsRevenue
Where the money comes from - by business line and by region, quarter by quarter.
Revenue, operating income and growth
quarterlyRevenue by business line
stacked, quarterly| Segment | Q2 '23 | y/y | Share | TTM | TTM y/y | 12 quarters |
|---|---|---|---|---|---|---|
| Total Oncology | $4.38B | +173.0% | 25.8% | – | – | |
| Oncology Products | – | – | – | – | – | |
| Cardiovascular Renal And Metabolism Products | – | – | – | – | – | |
| Farxiga | $1.51B | +447.3% | 8.9% | – | – | |
| Tagrisso | $1.49B | +190.6% | 8.8% | – | – | |
| BioPharmaceuticals: total Respiratory & Immunology | $1.48B | +126.8% | 8.7% | – | – | |
| Respiratory Products | – | – | – | – | – | |
| Imfinzi | $1.08B | +187.7% | 6.3% | – | – | |
| Covid19 | – | – | – | – | – | |
| Covid19 Vaccine Astrazeneca C19vaz | – | – | – | – | – | |
| Soliris | $814M | +41.8% | 4.8% | – | – | |
| Lynparza | $717M | +129.8% | 4.2% | – | – | |
| Ultomiris | $713M | +202.1% | 4.2% | – | – | |
| Symbicort | $600M | +170.3% | 3.5% | – | – | |
| Calquence | $653M | +64.9% | 3.8% | – | – | |
| Other Products | – | – | – | – | – | |
| Fasenra | $406M | +76.5% | 2.4% | – | – | |
| Nexium | $248M | +726.7% | 1.5% | – | – | |
| Brilinta | $331M | +78.9% | 1.9% | – | – | |
| Pulmicort | $124M | +726.7% | 0.7% | – | – | |
| Crestor | – | – | – | – | – | |
| Total Other medicines | $301M | +736.1% | 1.8% | – | – | |
| Strensiq | $300M | +55.4% | 1.8% | – | – | |
| Crestor. | $280M | +1,650.0% | 1.6% | – | – | |
| Faslodex | $78M | +1,460.0% | 0.5% | – | – | |
| Seloken Toprol Xl | – | – | – | – | – | |
| Zoladex | $233M | +7,666.7% | 1.4% | – | – | |
| Seloken/Toprol-XL | $164M | -26.5% | 1.0% | – | – | |
| Breztri | $163M | +207.5% | 1.0% | – | – | |
| Bydureon | $43M | -30.6% | 0.3% | – | – | |
| Other Respiratory Products | – | – | – | – | – | |
| Iressa | – | – | – | – | – | |
| Onglyza | $65M | +195.5% | 0.4% | – | – | |
| Lokelma | $100M | +156.4% | 0.6% | – | – | |
| Synagis | $87M | +4,250.0% | 0.5% | – | – | |
| Koselugo | $80M | +70.2% | 0.5% | – | – | |
| Roxadustat | $73M | +46.0% | 0.4% | – | – | |
| Respiratory, Others | $71M | +54.3% | 0.4% | – | – | |
| Losec Prilosec | – | – | – | – | – | |
| Other Cardiovascular Renal And Metabolism Products | – | – | – | – | – | |
| Saphnelo | $68M | +195.7% | 0.4% | – | – | |
| Enhertu | $67M | +272.2% | 0.4% | – | – | |
| Arimidex | – | – | – | – | – | |
| Casodex | – | – | – | – | – | |
| Atacand | – | – | – | – | – | |
| Daliresp Daxas | – | – | – | – | – | |
| Daliresp/Daxas | $17M | -68.5% | 0.1% | – | – | |
| Oncology, Others | $54M | +5,300.0% | 0.3% | – | – | |
| Other, Others | $53M | +783.3% | 0.3% | – | – | |
| Movantik Moventig | – | – | – | – | – | |
| Kanuma | $46M | +130.0% | 0.3% | – | – | |
| Andexxa | $45M | +150.0% | 0.3% | – | – | |
| Seroquel Xr Ir | – | – | – | – | – | |
| Other Products Others | – | – | – | – | – | |
| Other Oncology Products | – | – | – | – | – | |
| Vaxzevria | $28M | – | 0.2% | – | – | |
| Byetta | – | – | – | – | – | |
| Bevespi | $15M | +36.4% | 0.1% | – | – | |
| Symlin | – | – | – | – | – | |
| Other Diabetes | – | – | – | – | – | |
| Tudorza Eklira | – | – | – | – | – | |
| FluMist | $3M | +200.0% | 0.0% | – | – | |
| Flumist | – | – | – | – | – | |
| Duaklir | – | – | – | – | – |
Margins & cost structure
How much of each unit of revenue is left at each level - and where the costs go.
Margins
quarterlyCosts as % of revenue
quarterlyCash flow & capital allocation
Cash generated, what it is spent on, and what reaches shareholders.
Operating cash flow, capex, free cash flow
quarterlyUses of cash vs operating cash flow
fiscal yearsLast 4 quarters
cash flow statement- Operating cash flow
- $13.3B
- Capex
- -$4.01B
- Buybacks
- -$349M
- Dividends
- -$4.93B
- Acquisitions
- -$1.16B
- Net debt issued
- $793M
- Stock-based compensation
- $0
- Free cash flow
- $9.32B
- Returned to shareholders / FCF
- 56.6%
Share count and EPS
quarterly, dilutedBalance sheet
Liquidity, investments and debt at each quarter end.
Cash, investments and debt
quarter endsValuation & returns
Today's multiples against the company's own last five fiscal years; analyst targets and ratings.
Multiples and returns
TTM vs 5 fiscal years| Now | 5y average | Where today sits in the 5-year range | |
|---|---|---|---|
| P/E (TTM) | 26.3× | 320.5× | 26.6× – 1,448.1× |
| EV / EBITDA | 14.8× | 21.9× | 14.6× – 36.9× |
| EV / Sales | 5.1× | 4.9× | 4.2× – 5.3× |
| Price / FCF | 31.9× | 32.7× | 27.7× – 43.7× |
| Price / Book | 5.6× | 5.1× | 4.2× – 5.7× |
| FCF yield | 3.1% | 3.1% | 2.3% – 3.6% |
| Return on invested capital | 13.1% | 7.4% | -0.5% – 13.0% |
| Return on equity | 22.3% | 12.5% | 0.3% – 21.1% |
Analysts
Consensus target $186.67 (0.0%)
range $158.00 – $216.00 · rating Buy
Strong buy1
Buy19
Hold15
Sell6
Strong sell0
Outlook
Analyst consensus for the coming fiscal years and what it implies at today's price.
Consensus estimates
| Fiscal year | Revenue | Growth | EPS | Growth | P/E at today's price | Analysts (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $62.9B | +7.0% | $10.25 | +56.7% | 18.2× | 7 |
| FY2027 | $67B | +6.6% | $11.34 | +10.7% | 16.5× | 8 |
| FY2028 | $71.2B | +6.2% | $12.61 | +11.2% | 14.8× | 12 |
| FY2029 | $76.3B | +7.1% | $14.48 | +14.9% | 12.9× | 9 |
| FY2030 | $81.3B | +6.6% | $16.12 | +11.3% | 11.6× | 5 |
Financial statements
Every line of the income statement, balance sheet and cash flow statement - 12 quarters and 10 fiscal years, as values, as % of revenue or as growth.
Sources
Statements, segment revenue, metrics and estimates: Financial Modeling Prep.
Data as of 2026-11-01